Cambridge Investment Research Advisors, Inc. Lexicon Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 23,613 shares of LXRX stock, worth $17,237. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,613Holding current value
$17,237% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding LXRX
# of Institutions
133Shares Held
245MCall Options Held
52KPut Options Held
178K-
Artal Group S.A. Luxembourg, N4136MShares$99.4 Million100.0% of portfolio
-
Siren, L.L.C. New York, NY38.9MShares$28.4 Million1.27% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$7.22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.88MShares$7.21 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.99MShares$6.56 Million0.02% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $138M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...